Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREE-2 Study: Oxaliplatin Regimens + Bevacizumab in Advanced Colorectal Cancer
NCT00062426Phase 3Completed
- Sponsor
- Prologue Research
- Start
- May 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colorectal cancer (CRC) (3 arms), sponsored by Prologue Research. Primary endpoint: Incidence of Grade 3 and 4 Toxic Effects at 12 weeks. Started May 2003; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00062426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062426.